Related Experiment Video
Updated: Jan 22, 2026

Author Spotlight: Alleviating Nausea and Vomiting in Pregnancy with Safe and Effective Auricular Acupuncture
Published on: August 4, 2023
[Verification of Relationship between Administration of Linezolid and Vomiting]
Takezo Tsutsumi1, Shungo Imai1, Katsuhisa Yamada2
1Department of Pharmacy, Hokkaido University Hospital.
Abstract:
Linezolid (LZD), an antimicrobial agent against methicillin-resistant Staphylococcus aureus, demonstrates good bone and joint penetration, and is used for prosthetic bone and joint infections. Recently, we observed vomiting in several patients administered LZD. However, there are few reports on the incidence rate of, and risk factors for, LZD-induced nausea and vomiting. In this study, we aimed to verify the relationship between LZD administration and vomiting. Patients administered LZD at the Department of Orthopedic Surgery of Hokkaido University Hospital between November 2008 and December 2017 were enrolled in the study. The primary endpoint was the comparison of the vomiting rate between patients administered LZD (LZD group) and those administered other antibiotics (non-LZD group). For the secondary endpoint, to verify the risk factors of vomiting, a univariate logistic regression analysis was performed. In total, 130 patients were included in this study; 77 patients in the LZD group, and 53 in the non-LZD group. Vomiting occurred in 18 patients in the LZD group and 4 patients in the non-LZD group (23.4% and 7.5%, respectively); this was significantly higher in the LZD group. In the univariate logistic regression analysis, LZD administration, gender (female), age ≥65 years, renal impairment (creatinine clearance <60 mL/min) and concomitant use of rifampicin were extracted as potential risk factors of vomiting. The results of this study reveal a possible relationship between LZD administration and vomiting.
Insights
Linezolid (LZD) antibiotic use was linked to a higher incidence of vomiting in orthopedic patients. Potential risk factors include female gender, older age, renal impairment, and concurrent rifampicin use.
Area of Science:
- Infectious Diseases
- Pharmacology
- Orthopedic Surgery
Background:
- Linezolid (LZD) is an effective antibiotic for methicillin-resistant Staphylococcus aureus infections, including bone and joint infections.
- Nausea and vomiting are potential side effects of LZD, but incidence rates and risk factors are not well-documented.
Purpose of the Study:
- To investigate the relationship between Linezolid administration and the occurrence of vomiting.
- To identify risk factors associated with LZD-induced vomiting in orthopedic patients.
Main Methods:
- Retrospective study comparing vomiting rates in patients receiving LZD versus other antibiotics.
- Univariate logistic regression analysis to identify risk factors for vomiting.
Main Results:
- Vomiting occurred significantly more often in the LZD group (23.4%) compared to the non-LZD group (7.5%).
- Identified risk factors for vomiting included LZD administration, female gender, age ≥65 years, renal impairment, and concomitant rifampicin use.
Conclusions:
- Linezolid administration is associated with an increased risk of vomiting in orthopedic patients.
- Factors such as female gender, advanced age, renal impairment, and concurrent rifampicin use may further increase this risk.
More Related Videos
Related Concept Videos
Pathophysiology of Vomiting
Self-Evaluation: Self-Enhancement and Self-Verification
Strategies of Self-Presentation II: Self-Verification
Relationship Formation
Ending Relationships
Relationship Growth

